stable coronary artery disease (CAD) patients by comparing the results to an established, validated laboratory-based genotyping method. Methods: 74 stable CAD patients on clop 75 mg daily were tested by clinical nurses with no genetic laboratory experience and 1 hour of basic training on the device. The patients were defined as EM (*1/*1, *1/*17, *17/*17), RM (*1/*2A, *1/*8, *2A/*2A, *2A/*3). Genetic testing was conducted on 1 mL of whole blood using the Verigene® System and compared to an Affymetrix® DMETϩ assay. Pharmacokinetic (PK) exposure to clop's active metabolite (AM) was measured and platelet reactivity (PD) was assessed with the VerifyNow™ P2Y12 system (PRU) and VASP (PRI) assays. Results: There was an overall 99.9% concordance of marker-level data between the Verigene® and the reference (DMETϩ) in measuring the CYP2C19 markers of interest. There was a 100% agreement between Verigene® and the reference test in classifying the patients into established EM and RM groups. The POC assay identified 59 EM, 15 RM. The EM group had significantly lower PRU (LS means 158 vs. 212; pϭ0.003), and PRI (LS means 48 vs. 63, pϭ0.01) than RM group treated with clopidogrel 75 mg. The EM group also had significantly higher AM exposure by AUC(0-last) than the RM group (LS means 12.6 vs. 7.7; pϭ0.0009). Conclusions: This is the first report of a POC genetic testing platform performing a comprehensive CYP2C19 polymorphism characterization in CAD patients and validating the genotypes against the PK and PD phenotype. There was a high concordance between the two platforms in measuring the star allele marker data. The POC genetic test identified EM and RM phenotypes based on 11 gene variants with high accuracy and predicted a reduced platelet inhibition in response to clop. A rapid, reliable POC CYP2C19 genetic test could make clop pharmacogenetic testing feasible for all patients.
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Residual Platelet Reactivity Threshold After Clopidogrel Loading Dose to Predict Long-term Clinical Outcome in Patients with
Background: There is no consensus concerning the usefulness of routine assessment of in vitro platelet reactivity for recognition of clopidogrel nonresponders, or the method or methods that allow reliable assessment of residual platelet reactivity, and for each method the cutoff of platelet aggregation inhibition that should be used in clinical practice. Methods: The study includes 1,789 acute coronary syndrome (ACS) patients receiving an invasive treatment and for whom platelet reactivity after a 600 mg clopidogrel loading was prospectively assessed by light transmittance aggregometry (LTA). The primary end point of the study was a composite of cardiac death, myocardial infarction, any urgent coronary revascularization, and stroke (MACE) at 2-year follow-up; the secondary end point was cardiac mortality. The sensitivity and specificity of platelet reactivity to predict both end points were calculated in a ROC curve analysis. The ЉoptimalЉ cutoff value was defined by the highest Youden index value and compared with the predefined cutoff of 70% used in the main study and corresponding to the 90th percentile value derived from an healthy volunteer sample. Results: By ROC analysis 63% resulted the optimal cutoff value to predict both MACE and cardiac death at 2 years of follow-up. A significant sensitivity improvement for the ROC-based cutoff value was revealed (32%; pϽ0.001). The incidence of clopidogrel nonresponders changed from 14% with the cutoff of 70% to 24% with the ROC-based cutoff. However, the increased sensitivity was reached at the price of a lower specificity and accuracy. The latter with the cutoff of 70% was 81% for MACE and 84% for cardiac death, while with the cutoff of 63% the predictive accuracy was 73% and 75%, respectively. The AUCs were nearly identical with the 2 cutoffs both for MACE (0.71; 95% CI 0.69-0.73) and cardiac death (0.79; 95% CI 0.77-0.81).
Conclusions:
The cutoff of 70% as compared to the ROC-based of 63% allows the identification of a subset of patients at very high risk of cardiac death in only 14% of the studied population, making the ADP LAT test more acceptable in clinical practice for the identification of subjects at risk. Background: Glycoprotein IIb/IIIa inhibitors (GPI) are widely used during percutaneous interventions, particularly in the setting of high clot burden, slow flow, or no reflow. While the safety of a 300 mg clopidogrel loading dose in conjunction with GPI therapy has been established, the safety of a 600 mg clopidogrel load has not been defined. Methods: We searched PubMed, Cochrane, and ClinicalTrials.gov for studies that involved PCI in patients treated with a GPI plus either 300 mg or 600 mg of clopidogrel. We excluded studies that involved oral or intracoronary GPI therapy and/or thrombolysis. Results: Our study included 15 trials and 12,114 patients. Major bleeding incidence ranged from 0% to 10.36% with 300 mg of clopidogrel versus 1.11% to 7.52% with 600 mg of clopidogrel. Minor bleeding incidence ranged from 0% to 25.69% with 300 mg of clopidogrel and from 0% to 6.13% with 600 mg of clopidogrel. After excluding trials that did not define bleeding based on TIMI criteria, the pooled incidence of major bleeding was 1.08 (95% CI, 0.74 to 1.42)% for the 300 mg clopidogrel group and 1.46 (95% CI, 1.02-1.90)% for the 600 mg clopidogrel group (pϭ0.91) ( Figure 1A ). The pooled incidence of TIMI minor bleeding was 2.15 (95% CI, 0.44 to 3.86)% for the 300 mg group and 3.66 (95% CI, 2.54 to 4.79)% for the 600 mg group (pϭ0.46) ( Figure 1B) .
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Conclusions:
Among patients undergoing PCI and receiving a GPI, the incidence of bleeding is low and similar after a 300 mg or 600 mg clopidogrel loading dose.
TCT-728
Clinical presentations, antiplatelet strategies and prognosis of patients with stent thrombosis: an observational study of 140 patients Background: Until now there has been scarce evidence regarding an optimal antiplatelet strategy and clinical outcomes for patients who had suffered from stent thrombosis (ST). Methods: 140 patients who suffered from stent thrombosis were prospectively registered. Patients received dual (aspirin and 150mg clopidogrel, Nϭ66) or triple (additional cilostazol, Nϭ74) antiplatelet therapy at the physician's discretion. Thereafter platelet reactivity and one year clinical outcomes were analyzed. The primary outcome included the composite of cardiac death, non-fatal myocardial infarction (MI) or stroke at one year. Results: MACE developed in 41 (29.3%) patients, consisting of 31 (22.1%) cardiac death, 9 (6.4%) non-fatal MI and 1 (1.4%) stroke. Recurrent definite and probable ST according to ARC definition was observed in 8 (5.7%) and 14 (10.0%) patients, respectively. Triple therapy was associated with significantly lower platelet reactivities (50.2Ϯ17.8, % vs. 59.6Ϯ17.2, %, Pϭ0.002) compared to high dose dual antiplatelet therapy. However, the incidence of primary events (24.3% vs. 34.8%, Pϭ0.172) did not differ between triple and dual antiplatelet therapies. High on-treatment platelet reactivity (HR: 8.35, 95% CI: 2.234ϳ30.867, Pϭ0.002) and diabetes (HR: 3.732, 95% CI: 1.353ϳ10.298, Pϭ0.011) were independent predictors of primary events. Conclusions: Patients who suffered from stent thrombosis have a poor prognosis even after revascularization with intensive antiplatelet therapy. Triple antiplatelet therapy was more effective in reducing on-treatment platelet reactivity, compared to high dose dual antiplatelet therapy. 
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Discontinuation of Long-Term Clopidogrel Therapy is Associated with Death and Myocardial Infarction after Saphenous Vein Graft Percutaneous Coronary Intervention
Background:
The timing and incidence of adverse events by different durations of clopidogrel therapy after SVG PCI remain unknown. The primary objective of this study was to investigate the risk associated with cessation of long-term clopidogrel therapy after SVG PCI. Methods: This is a cohort study of patients undergoing SVG PCI from 2000-2009 followed for death or MI after stopping clopidogrel. A piecewise exponential survival model was used to generate adjusted incidence rate ratios comparing the 0-90 day and 91-365 day intervals after clopidogrel cessation. A multivariate Cox regression model was constructed to obtain risk-adjusted instantaneous incidence rates using kernel hazard functions. 
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